A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GZR4 in Subjects With Type 2 Diabetes

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 22, 2023

Primary Completion Date

November 1, 2023

Study Completion Date

November 1, 2023

Conditions

Diabetes

Interventions

DRUG

GZR4

Administered once weekly subcutaneously (s.c., under the skin) for 6 weeks

DRUG

Insulin Degludec

Administered once daily subcutaneously (s.c., under the skin) for 6 weeks

Trial Locations (1)

Gan & Lee Pharmaceuticals Co., Ltd, Beijing